

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 18. (Canceled)

19. (Currently Amended) ~~A method~~Method for diagnosis ~~or~~and therapy of tumours ~~or a~~
~~and diseases characterized by~~ vascular proliferation disease in a patient comprises administering
an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain
with the following amino acid sequence:

VH domain (SEQ ID NO: 30)

<u>EVQLLES</u>	<u>GGG</u>	<u>LVQPGG</u>	<u>SLRL</u>	<u>SCAASG</u>	<u>FTFS</u>
<u>SFSMSW</u>	<u>VRQA</u>	<u>PGKGLE</u>	<u>WVSS</u>	<u>ISGSSG</u>	<u>TTTY</u>
<u>ADSVKGR</u>	<u>FTI</u>	<u>SRDNSK</u>	<u>NLTLY</u>	<u>LQMNSL</u>	<u>RAED</u>
<u>TAVYYCA</u>	<u>KPF</u>	<u>PYFDYW</u>	<u>GQGT</u>	<u>LVTVSS</u>	

and having a VL domain with the amino acid sequence encoded by the VL domain
encoding DNA of the DNA insert of ATCC deposit no. PTA-9529, wherein an antibody with
specific affinity for a characteristic epitope of the ED-B domain of fibronectin, said antibody
having improved affinity to said ED-B domain, is used.

20. (Currently Amended) ~~A conjugate~~Conjugate comprising (a) an antibody with
specific, high affinity for the ED-B domain of fibronectin having a VH domain with the
following amino acid sequence:

VH domain (SEQ ID NO: 30)

<u>EVQLLES</u>	<u>GGG</u>	<u>LVQPGG</u>	<u>SLRL</u>	<u>SCAASG</u>	<u>FTFS</u>
<u>SFSMSW</u>	<u>VRQA</u>	<u>PGKGLE</u>	<u>WVSS</u>	<u>ISGSSG</u>	<u>TTTY</u>

ADSVKGRFTI SRDNSKNTLY LQMNSLRAED
TAVYYCAKPF PYFDYWGQGT LVTVSS

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529; an antibody according to claim 1 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

21. (Currently Amended) A conjugate~~Conjugates~~ according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

22. (Currently Amended) A conjugate~~Conjugates~~ according to claim 21 wherein the photoactive molecule is a photosensitizer.

23. (Currently Amended) A conjugate~~Conjugates~~ according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

24. (Currently Amended) A conjugate~~Conjugates~~ according to claim 22 wherein the photosensitizer is a derivative of tin (IV) chloride.

25. (Currently Amended) A conjugate~~Conjugates~~ according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

26. (Currently Amended) A conjugate~~Conjugates~~ according to claim 25 wherein the radionuclide is ~~an α -~~ or β - emitting radionuclide.

27. (Canceled)

28. (Currently Amended) A conjugate~~Conjugates~~ according to claim 20 comprising a

~~wherein the molecule capable of inducing blood coagulation and blood vessel occlusion which is represented by a photosensitizer and a molecule which is a radionuclide.~~

29. (Currently Amended) ~~A method~~Method for the treatment of an angiogenesis-related pathology in a patient comprising administering pathologies wherein a conjugate according to claim 20 ~~is injected.~~

30. (Currently Amended) ~~A method~~Method for the treatment of an angiogenesis-related pathology in a patient comprising administering pathologies wherein a conjugate according to claim 22 ~~by injection is injected,~~ followed by irradiating said patient~~irradiation.~~

31. (Currently Amended) ~~A method~~Method according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

32. (Currently Amended) ~~A method~~Method for the treatment of an angiogenesis-related pathology comprising administering pathologies wherein a radionuclide-containing conjugate according to claim 25 ~~by injection is injected.~~

33. (Currently Amended) ~~A method~~Method according to claim 32 wherein the radionuclide is astatine-211.

34. (Currently Amended) ~~A method~~Method for the treatment of an angiogenesis-related pathology comprising administering pathologies wherein a conjugate according to claim 28 ~~by injection is injected.~~

35. (Canceled)

36. (New) A conjugate of claim 20 wherein the antibody further comprises a linking sequence with the amino acid sequence encoded by the linker-encoding DNA of the DNA insert

of ATCC deposited no. PTA-9529.

37. (New) A conjugate of claim 36 wherein the antibody is radiolabeled.
38. (New) A conjugate of claim 37 wherein the antibody is radioiodinated.
39. (New) A conjugate of claim 36 wherein the antibody is an ScFv antibody.
40. (New) A conjugate of claim 39 wherein the antibody is produced recombinantly.
41. (New) A conjugate of claim 36 wherein the ED-B domain of fibronectin is a human ED-B domain.
42. (New) A conjugate of claim 36 wherein the antibody is monoclonal.
43. (New) A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.
44. (New) A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin having VH, VL and linker domains with the amino acid sequences encoded, respectively, by the VH-, VL- and linker-DNA of the DNA insert of ATCC deposit no. PTA-9529 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.
45. (New) A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin and having a VH domain linked to a VL domain, wherein said VH domain has the following amino acid sequence:

VH domain (SEQ ID NO: 30)

E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S

SFSMSWVRQA	PGKGLEWVSS	ISGSSGTTY
ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED
TAVYYCAKPF	PYFDYWGQGT	LVTVSS,

and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion